Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
Gilead‘s experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. None of the roughly 2,000 women in the trial who received the lenacapavir shot had contracted HIV by an interim analysis, prompting the independent data monitoring committee to recommend Gilead unblind the Phase 3 trial and offer […]
Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial Read More »